Trial
NCT01662726
A Study to Assess the Ability of a Novel Endocrine Treatment for Breast Cancer, Irosustat, to Slow Down Cancer Growth
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Imperial College London
Collaborators
National Institute for Health Research, United Kingdom; Ipsen; Imperial College Healthcare NHS Trust; Guy's and St Thomas' NHS Foundation Trust; University of Southern California; QPS Netherlands B.V.
Condition
Breast Neoplasms
Intervention
Irosustat
Why stopped
Recruitment challenging: lack of suitable pts; recruiting so soon after diagnosis; competing studies. Funding ended despite extensions to grant.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-03-14